Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Hennigan

Fayetteville, AR Medical Doctor

NPI 1386728996 CMS profile 107829

4038 N Remington Dr Ste 4, Fayetteville, AR 72703

Open in the dashboard

General payments

$9,377

456 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Hennigan of Fayetteville, AR is reported in the CMS Open Payments database as having received $9,377 across 456 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $709 33
2024 General $986 42
2023 General $1,351 71
2022 General $2,721 94
2021 General $1,758 92
2020 General $792 46
2019 General $1,061 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Hennigan
  • Arkansas median
  • Middle half of Arkansas
  • National median

In program year 2025, general payments to Stephen Hennigan were reported at $709. Among 8,629 Arkansas profiles paid that year, the median was $170 and the middle half received between $48 and $585.

Show as a table
Year Stephen Hennigan Arkansas median Middle half National median
2019 $1,061 $156 $50–$572 $163
2020 $792 $115 $35–$373 $114
2021 $1,758 $125 $37–$439 $132
2022 $2,721 $154 $43–$530 $149
2023 $1,351 $169 $50–$565 $160
2024 $986 $160 $48–$544 $164
2025 $709 $170 $48–$585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $1,674 91 payments
  2. Cumberland Pharmaceuticals, Inc. $1,608 33 payments
  3. Insmed, Inc. $1,180 60 payments
  4. Gilead Sciences, Inc. $1,029 52 payments
  5. AbbVie, Inc. $961 60 payments
  6. Merck Sharp & Dohme Corporation $583 40 payments
  7. Paratek Pharmaceuticals, Inc. $402 15 payments
  8. La Jolla Pharmaceutical Company $372 21 payments
  9. Astellas Pharma US Inc $372 15 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $342 17 payments
  11. Other $854 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,261 454 payments
  2. Education $116 2 payments
Products named General payments · program years 2019–2025
  1. VIBATIV $1,434 26 payments
  2. Arikayce $1,141 58 payments
  3. DOVATO $1,138 62 payments
  4. AVYCAZ $797 49 payments
  5. DALVANCE $409 29 payments
  6. NUZYRA $402 15 payments
  7. XERAVA $400 23 payments
  8. DIFICID $387 27 payments
  9. CABENUVA $360 19 payments
  10. ZERBAXA $306 20 payments
  11. Other $3,167 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,100

Median for Infectious Disease: 268

Drug cost

$1,224,289

Median for Infectious Disease: $217,595

Branded share of claims

52.2%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 147 $576,496
Juluca Dolutegravir/Rilpivirine Brand 35 $122,494
Daptomycin Generic 98 $114,858
Descovy Emtricitabine/Tenofov Alafenam Brand 45 $99,206
Dovato Dolutegravir Sodium/Lamivudine Brand 34 $98,969
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 19 $67,074
Isentress Hd Raltegravir Potassium Brand 18 $35,362
Isentress Raltegravir Potassium Brand 12 $25,198
Pifeltro Doravirine Brand 13 $22,349
Ertapenem Ertapenem Sodium Brand 47 $18,694

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$308,190

Of which drugs: $216,194

Medicare patients

356

Average age 72

Services billed

80,913

159 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 51%
Chronic kidney disease 49%
Diabetes 48%
Depression 48%
Heart failure 44%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arikayce
  • Insmed, Inc. $236
$236 — —
DOVATO
  • ViiV Healthcare Company $80
$80 34 —
CABENUVA
  • ViiV Healthcare Company $59
$59 — —
DALVANCE
  • AbbVie, Inc. $47
$47 — —
AVYCAZ
  • AbbVie, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

456 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record